Adding Catheter Ablation to Standard Anticoagulation Did Not Cut Stroke Risk in Atrial Fibrillation Patients

Atrial fibrillation is the most common cardiac arrhythmia worldwide and one of the leading causes of ischemic stroke. When the heart beats irregularly, blood can pool in the left atrial appendage and form clots that travel to the brain. Oral anticoagulants - blood-thinning drugs that reduce clot formation - are the established first-line defense for stroke prevention in these patients.

But anticoagulants only address the clotting consequence of atrial fibrillation. They do not treat the underlying rhythm disorder. Catheter ablation - a procedure that uses radiofrequency energy or extreme cold to destroy the abnormal electrical tissue driving the arrhythmia - can restore normal heart rhythm in many patients. Whether restoring that rhythm, on top of anticoagulation, reduces stroke risk beyond anticoagulation alone has been an open clinical question.

A randomized trial led by Kazumi Kimura and colleagues, published in JAMA Neurology, attempted to answer that question in a population with an especially high baseline risk: patients with atrial fibrillation who had already experienced a stroke.

What the Trial Did and Found

Participants with atrial fibrillation and a documented recent stroke history were randomized to receive either standard oral anticoagulant therapy alone or anticoagulant therapy plus catheter ablation. The primary endpoint combined stroke recurrence, systemic embolism, and all-cause mortality.

The addition of catheter ablation did not produce a statistically significant reduction in the primary composite endpoint. Patients in both groups experienced similar event rates during follow-up.

The investigators note a critical limitation: the event rate observed during the trial was substantially lower than the rate assumed when the trial was designed. When fewer events occur than expected, a trial loses statistical power - the ability to detect a real difference between treatment groups even if one exists. The authors conclude that the study was likely underpowered and that a null result under these circumstances does not rule out a meaningful clinical benefit from adding ablation to anticoagulation.

What Underpowering Means for Interpreting the Results

The concept of an underpowered trial is important for understanding what these results do and do not tell us. Statistical power depends on the number of events that occur, not just the number of participants. If a trial expects 100 strokes across both groups and only 40 occur, the trial has roughly half the statistical sensitivity originally planned. Real differences between treatments may exist but remain undetectable with the available data.

This is not a flaw unique to this trial - event rates in secondary stroke prevention studies have been declining over recent decades as anticoagulant therapy has improved. Patients on modern oral anticoagulants have substantially lower stroke rates than patients in earlier eras, making it harder to demonstrate additional benefit from any add-on intervention.

The Broader Question Remains Open

The question of whether catheter ablation reduces stroke risk - particularly in patients who have already had one stroke - carries significant clinical weight. Survivors of atrial fibrillation-related stroke face elevated risk of recurrence, and any intervention that further reduces that risk could prevent substantial disability and death.

Several ongoing and planned trials are examining the combination of ablation and anticoagulation in different atrial fibrillation populations, with revised power calculations that account for contemporary event rates. The current trial adds to a pattern in this field where promising mechanistic rationale has repeatedly been harder to confirm in adequately powered clinical trials.